{{medical}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 462253627
| IUPAC_name = (''R'',''E'')-2-(1-((1-(3-(2-(7-Chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)cyclopropyl)acetic acid
| image = Montelukast2DCSD.svg
| width = 250
| image2 = Montelukast 3D ball-and-stick.png
| width2 = 250px
<!--Clinical data-->
| tradename = Singulair, others
| Drugs.com = {{drugs.com|monograph|montelukast-sodium}}
| MedlinePlus = a600014
| pregnancy_AU = B1
| pregnancy_US = B
| legal_US = Rx-only
| legal_CA = Rx-only
| legal_UK = POM
| legal_AU = S4
| routes_of_administration = By mouth
| class = {{tsl|en|Leukotriene receptor antagonist||Leukotriene receptor antagonist}}
<!--Pharmacokinetic data-->
| bioavailability = 63–73%
| protein_bound = 99%
| metabolism = [[Liver|Liver]] ([[CYP2C8|CYP2C8]]-major, [[CYP3A4|CYP3A4]] and [[CYP2C9|CYP2C9]]-minor)
| elimination_half-life = 2.7–5.5 hours
| excretion = Biliary
<!--Identifiers-->
| IUPHAR_ligand = 3340
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 158966-92-8
| ATC_prefix = R03
| ATC_suffix = DC03
| PubChem = 5281040
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00471
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4444507
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = MHM278SD3E
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08229
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 50730
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 787
<!--Chemical data-->
| C=35 | H=36 | Cl=1 | N=1 | O=3 | S=1
| molecular_weight = 586.184 g/mol
| SMILES = O=C(O)CC1(CC1)CS[C@@H](c2cccc(c2)\C=C\c3nc4cc(Cl)ccc4cc3)CCc5ccccc5C(O)(C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UCHDWCPVSPXUMX-TZIWLTJVSA-N
| melting_point = 145
| melting_high = 148
}}

'''孟鲁司特'''（Montelukast），化学式C<sub>35</sub>H<sub>36</sub>ClNO<sub>3</sub>S，商业使用时主要使用其钠盐，主要用于[[哮喘|哮喘]]治疗。1998年投入商业使用。药品名称中的“Mont”来自地名[[蒙特利尔|蒙特利尔]]，是[[默克药厂|默克药厂]]开发此药的地方。孟鲁司特是口服药。<ref name=AHFS2018>{{cite web |title=Montelukast Sodium Monograph for Professionals |url=https://www.drugs.com/monograph/montelukast-sodium.html |website=Drugs.com |publisher=AHFS |accessdate=23 December 2018 |language=en}}</ref>

<!-- 副作用及機制 -->
常見的副作用包括腹痛、咳嗽及頭痛<ref name=AHFS2018/>，嚴重的副作用包括過敏反應，像是[[過敏性休克|過敏性休克]]或{{le|嗜酸性球增多|eosinophilia}}<ref name=AHFS2018/>，在懷孕時使用應該是安全的<ref name=AHFS2018/>。孟鲁司特屬於{{le|白三烯受體拮抗劑|leukotriene receptor antagonist}}<ref name=AHFS2018/>，其作用是阻止肺中[[白三烯|白三烯]]D4的作用，因此可以減輕發炎，也可以讓[[平滑肌|平滑肌]]放鬆<ref name=AHFS2018/>。

<!-- 社會和文化 -->
孟鲁司特在1998年核准在美國使用<ref name=AHFS2018/>，是[[通用名药物|通用名药物]]<ref name=BNF76>{{cite book|title=British national formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|page=269|edition=76}}</ref>。2018年在美國每一劑的成本不到美金0.15元<ref>{{cite web |title=NADAC as of 2018-12-19 |url=https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-as-of-2018-12-19/g7bs-ahj4 |website=Centers for Medicare and Medicaid Services |accessdate=22 December 2018 |language=en}}</ref>，在英國每一劑的成本約為一磅<ref name=BNF76/>。2016年此藥物在美國的處方量是第23名，超過2500萬劑<ref>{{cite web |title=The Top 300 of 2019 |url=https://clincalc.com/DrugStats/Top300Drugs.aspx |website=clincalc.com |accessdate=22 December 2018}}</ref>。
==参考文献==
{{reflist}}
{{默克公司}}
[[Category:默克公司|Category:默克公司]]
[[Category:喹啉|Category:喹啉]]
[[Category:氯代芳烴|Category:氯代芳烴]]
[[Category:硫醚|Category:硫醚]]
[[Category:环丙基化合物|Category:环丙基化合物]]
[[Category:RTT|Category:RTT]]